Table 2.
Clinical characteristics and selected laboratory abnormalities of flu, COVID-19 and coinfection patients.
| Influenza (n = 41) | COVID-19 (n = 75)a | Coinfection (Influenza A/B, n = 23)b | P valuea,b | |
|---|---|---|---|---|
| Clinical characteristics | ||||
| Fever(≥ 37.3°C) | 36 (87.80%) | 52 (69.33%) | 15 (65.22%) | 0.0263, 0.7989 |
| Cough | 21 (51.22%) | 49 (65.33%) | 9 (39.13%) | 0.1662, 0.0310 |
| Nasal obstruction and rhinorrhea | 12 (29.27%) | 7 (9.33%) | 5 (21.74%) | 0.0083, 0.1454 |
| Sore throat | 4 (9.76%) | 14 (18.67%) | 4 (17.39%) | 0.2855, 1.0000 |
| Shortness of breath and chest tightness | 3 (7.32%) | 9 (12.00%) | 2 (8.70%) | 0.5353, 1.0000 |
| Fatigue | 4 (9.76%) | 27 (36.00%) | 6 (26.09%) | 0.0023, 0.3788 |
| Diarrhea and vomiting | 3 (7.32%) | 7 (9.33%) | 2 (8.70%) | 1.0000, 1.0000 |
| Blood routine | ||||
| WBC count(× 109/L) | 5.18 (3.71, 8.12) | 5.52 (4.19, 7.24) | 5.34 (4.51, 6.23) | 0.2112, 0.6358 |
| (≤ 3.5 × 109/L) | 13 (31.71%) | 9 (12.00%) | 1 (4.35%) | 0.0096, 0.2889 |
| Lymphocyte count (× 109/L) | 1.20 (0.83, 1.62) | 1.23 (0.90, 1.59) | 1.39 (1.05, 1.76) | 0.9678, 0.0627 |
| (≤ 1.1 × 109/L) | 15 (36.59%) | 20 (26.67%) | 5 (21.74%) | 0.2659, 0.6353 |
| CRP (mg/L) | 7.43 (4.26, 17.40) | 13.63 (3.93, 26.60) | 14.82 (4.87, 28.41) | 0.0617, 0.2026 |
| (≥5mg/L) | 21 (51.22%) | 53 (70.67%) | 14 (60.87%) | 0.0372, 0.3768 |
| ESR(mm/h) | 18 (7.50, 33.50) | 17 (7.00, 31.50) | 21.5 (9.50, 41.00) | 0.4271, 0.5078 |
| (≥15 mm/h) | 22 (53.66%) | 36 (48.00%) | 12 (52.17%) | 0.6979, 0.7261 |
| (D-dimer mg/L) | 0.17 (0.10, 0.28) | 0.25 (0.14, 0.34) | 0.28 (0.18, 0.37) | 0.0046, 0.1246 |
| (≥0.25 mg/L) | 15 (36.58%) | 28 (37.33%) | 12 (52.17%) | 0.4311, 0.0018 |
| Creatine kinase (U/L) | 104 (66.30, 149.60) | 118 (78.50, 158.30) | 115 (62.40, 175.20) | 0.1157, 0.8316 |
| (≥171 U/L) | 1 (2.44%) | 12 (16%) | 7 (30.43%) | 0.0013, 0.0027 |
| BUN (mmol/L) | 4.43 (3.69, 5.26) | 4.38 (3.52, 5.21) | 4.50 (3.76, 5.03) | 0.9550, 0.5377 |
| Creatinine (μmol/L) | 86.32 (78.90, 92.90) | 90.94 (74.70, 108.10) | 97.99 (76.70, 118.04) | 0.0008, 0.1659 |
| (≥104μmol/L) | 3 (7.32%) | 18 (24%) | 6 (26.09%) | 0.0239, 0.5840 |
The data was shown as n (%) or median (IQR).
a
COVID-19 vs. Influenza group.
b
Coinfection vs. COVID-19 group.